How Tremelimumab Targets Cancer Cells
Tremelimumab is a monoclonal antibody that blocks CTLA-4, a protein on T cells. CTLA-4 acts as an immune checkpoint, inhibiting T-cell activation to prevent overactive immune responses. By binding CTLA-4, tremelimumab removes this brake, allowing T cells to proliferate and attack cancer cells more aggressively.[1][2]
CTLA-4 Mechanism in Detail
Normally, CTLA-4 competes with CD28 on T cells for binding to B7 molecules on antigen-presenting cells. CD28 binding activates T cells, while CTLA-4 binding suppresses them. Tremelimumab has higher affinity for CTLA-4 than B7, blocking the interaction and tipping the balance toward T-cell activation. This unleashes cytotoxic T cells against tumors expressing specific antigens.[1][3]
How It Differs from PD-1/PD-L1 Inhibitors
Unlike PD-1 inhibitors (e.g., nivolumab) that act later in the T-cell response at the tumor site, tremelimumab targets CTLA-4 early during T-cell priming in lymph nodes. This leads to broader, less tumor-specific immune activation, increasing efficacy but also autoimmune risks. Combinations like tremelimumab with durvalumab (a PD-L1 inhibitor) enhance responses by hitting both checkpoints.[2][4]
Clinical Use and Approvals
FDA approved tremelimumab (Imjudo) in 2022 with durvalumab for unresectable hepatocellular carcinoma, based on HIMALAYA trial data showing improved survival. It received accelerated approval for metastatic urothelial carcinoma in 2024. Dosing is typically fixed at 75 mg IV every 4 weeks with durvalumab.[4][5]
Common Side Effects from Immune Activation
Blocking CTLA-4 often causes immune-related adverse events like colitis, dermatitis, hepatitis, and endocrinopathies due to unchecked T-cell activity. Severe cases (grade 3-4) occur in 20-30% of patients, managed with corticosteroids or immunosuppressants. Monitoring requires frequent labs and early intervention.[3][5]
Ongoing Trials and Combinations
Tremelimumab features in over 100 trials, testing combos with PD-1/PD-L1 drugs, chemotherapy, or vaccines for lung, head/neck, and mesothelioma cancers. POSIUM trial explores single-agent use in advanced solid tumors.[4]
Sources
[1] Nature Reviews Drug Discovery: CTLA-4 inhibitors
[2] FDA Label: Imjudo
[3] New England Journal of Medicine: Tremelimumab mechanism
[4] ClinicalTrials.gov: Tremelimumab studies
[5] AstraZeneca prescribing information